Why Is Capital Repeatedly Betting on Juxin Medical? The Company Secures Nearly RMB 200 Million in Series C Funding

Recently, CONMIND MEDICAL (Zhongshan) Co., Ltd. (hereinafter referred to as“Conmind”) Officially announced the completion of nearly2100 million RMBCThis round of financing was led by the Zhongshan Biomedical Angel Fund under Zhongshan Venture Capital, with co-investment from the biomedical fund under Yucai Zhongyin, Yueke Financial, and other institutions. The existing shareholder, Zhuhai High-Tech Golden Investment, continued to increase its investment, and Xiqiao Capital served as the exclusive financial advisor.

From2021Since its establishment in [Year], in just over two years, CONMIND MEDICAL has successively completedBWheel,B+Wheel,CRound C financing, with a cumulative financing amount exceeding3billion yuan, becoming a leader in the field of brain medicine and cardiovascular intervention.“Financing Dark Horse”。

Amid the current wave of financing and reshuffling in the brain-computer interface sector, why is capital continuing to bet on this young company? What is Conmind's core competitiveness? What are the underlying dynamics of the sector that have fueled its rapid rise?

Financing Code:Three Rounds of Capital Boost, Backed by Three Core Logics

Conmind's financing pace has always been in line with the company’s development and industry trends, with each round of financing precisely meeting the needs of development. This is the core reason for continued capital favor.

Looking back at its financing journey, every step is clearly visible:

2023Year8Month, completing nearly 100 million yuanBRound Financing, with investors including Chengdu Chuanhe Ruiqi, Turing Asset Management, Zhuhai High-tech Investment, etc. All funds are directed towards clinical trials and early commercialization of innovative cardiovascular and cerebrovascular products, laying a solid industrial foundation for the company;

2024Year11Month, CompletedB+Round of financing, amount not disclosed, with the participation of institutions such as Rongyi Capital, Chenhai Capital, and Shanghai Bank International, further supporting the iteration of core products and channel expansion;

This recent2100 Million YuanCThe round of financing focuses on the research and development and industrialization of brain-computer interface technology., marking the official entry of the company into“Interventional Devices+Brain-Computer Interface”A New Phase of Dual-Driven Development.

Behind the continued increase in capital investment lie three logic points that cannot be ignored.

First, the track dividend is prominent., brain-computer interface has been incorporated into“155”One of the six planned future industries,2026It was even written into the government work report this year, becoming a key future industry to be cultivated. With the叠加of policy and market benefits, the track's growth potential is clear.

Secondly, the company's commercialization capabilities are outstanding.Compared with most brain-computer interface companies that are still in the laboratory stage, Conmind has achieved the commercialization of cardiovascular and cerebrovascular interventional products at an early stage, with stable cash flow and stronger risk resistance.

Thirdly, the team and technology are scarce., the core team possesses both R&D and commercialization experience. The technical accumulation in the interventional device field provides a unique advantage for the clinical implementation of brain-computer interfaces, this kind of“First Devices, Then Brain-Computer”The layout model has become its core highlight that sets it apart from its peers.

Product Barriers:“Intervention+Brain-Computer”Integration, Build Differentiated Competitiveness

In the field of brain medicine, the core competitiveness of CONMIND MEDICAL lies in breaking away from“Single Technology Development”Misconceptions, paving a unique path“Interventional Devices+Brain-Computer Interface”The path of integration has formed a differentiated barrier that is difficult to replicate.

As a company that started with cardiovascular and cerebrovascular interventional devices, Conmind has built a complete product matrix:NeurointerventionCovering flow diverter stents, intracranial stents, coil embolization systems, and various catheters and guidewires,Among them, the subsidiary of the group, CONMIND MEDICAL, developedJ‑Tube™Flow Diverter Stent Gains NMPA Market Approval on January 6, 2025；

Cardiac InterventionFocusing on Minimally Invasive Repair of Mitral and Tricuspid Valves,HaloChord® Transcatheter Mitral Chordae Repair SystemWith the clinical advantages of minimal trauma and rapid recovery, it fills the technical gap in China and enters the innovative medical device field.“Green Channel”。

As of now,The company has applied for more than200 Items, with a Class III medical device registration certificate10 Sheets, Localization rate of core materials and production equipment exceeds95%。

On this basis, CONMIND MEDICAL proposed“Nourishing the Heart, Protecting the Brain”The innovative concept deeply integrates cardiovascular and cerebrovascular interventional treatment with brain-computer interface technology, creating“Physical Restoration+Functional Reconstruction”Full-cycle Solution——Interventional Devices for Cardiovascular and Cerebrovascular Diseases“Structural Repair”Problem, brain-computer interface achieves neural function“Reconstruction and Regulation”，Especially in stroke scenarios, seamless integration.“Vascular Unblocking”And“Neuromodulation”The clinical needs, this logic fits the clinical reality, and also gives its brain-computer interface technology a natural advantage for implementation.

Compared with peers, this integration advantage is more prominent: compared with companies like MicroPort NeuroTech and Peijia Medical, which mainly focus on interventional devices, Conmind has a first-mover advantage with its forward-looking layout in the brain-computer interface field; compared with companies like BrainLu Technology that specialize in brain-computer interface R&D, Conmind’s mature clinical transformation capabilities and commercialization channels can accelerate technology implementation and avoid...“Technology and Market Disconnect”Pain points.

Track Opportunities:Policy+Driven by Dual Demands, Broad Development Space

The rapid rise of Conmind is inseparable from the vigorous development of the brain medicine sector, while policy support and market demand have provided it with broad growth space.

At the policy level, the central and local governments are working together to provide support and protection for the brain-computer interface industry.“155”Brain-computer interface is listed as a key future industry for development in the plan, and it is also listed as one of the seven key investment areas by the national venture capital guidance fund.; Local governments such as Zhongshan and Zhuhai have introduced R&D subsidies and industrialization support policies. Moreover, Zhongshan, where CONMIND MEDICAL is registered, has even identified brain-computer interface as2026The key future industries cultivated in the year provide ample policy support for enterprise development.

At the demand level, the intensification of population aging has given rise to a huge market. Currently, in China65The proportion of the population aged above has reached14%Patients with neurological diseases such as stroke, Parkinson's disease, and epilepsy represent a large population base, with a consistently strong demand for medical rehabilitation.

On April 1, 2026, the "China Brain-Computer Interface Commercialization Prospective Report" released by Beijing Fourth Wave Technology Think Tank in collaboration with Zhongguancun Tiancheng Innovation Research Center showed that since 2025, brain-computer interface companies have entered an unprecedented active period of financing.In the first three months of 2026, the total financing amount of brain-computer interface enterprises has exceeded that of the entire year of 2025.The report predicts that by 2026, the market size of brain-computer interface in China is expected to exceed 5 billion yuan and maintain rapid growth, and by 2030, it is expected to exceed 15 billion yuan.

At the same time, the industry is welcoming“Golden Window Period”，2026The year is regarded as the first year of large-scale application of brain-computer interface. Invasive and non-invasive technologies have made breakthroughs at multiple points, and the commercial closed-loop is about to be打通. Conmind focuses on interventional brain-computer interfaces, which are not only technologically advanced but also meet clinical needs, hitting the sweet spot of track development.

Future Layout: Focus on Clinical Implementation, Sprint to the Top of the Brain Medicine Track

This timeCThe completion of the round of financing has injected strong momentum into Conmind's future development. Combined with the use of funds, its short-term development path is clearly visible. In the future1-2This year, the company will focus on advancing three key initiatives: first, tackling the core technologies of brain-computer interfaces, breaking through critical bottlenecks such as neural signal acquisition, decoding algorithms, and flexible electrodes; second, iterating core components to optimize the biocompatibility and signal stability of interventional brain-computer interface devices; third, accelerating industrialization by building dedicated production lines, advancing multi-center clinical trials, and promoting the transition of brain-computer interface technology from laboratory to clinical application.

Founder,CEOHuang Hui once said:“Clinical problems are opportunities for innovation.”This concept runs through the entire process of enterprise development and also determines the development direction of Conmind.——Not blindly chasing technology hotspots, but focusing on clinical needs, through“Intervention+Brain-Computer”The integration and innovation provide patients with more precise and efficient diagnosis and treatment solutions. Currently, the company has completed the establishment of commercial channels across China, achieved commercial implementation of stroke treatment-related products, and simultaneously initiated expansion into overseas markets, laying the foundation for subsequent product scaling.

What capital bets on is not only the future of the track but also the strength of the enterprise.

Three Rounds of Financing in Two Years, Can Conmind Become the“Potential Stock”, never by chance——It has both capitalized on the红利 of the brain-computer interface track and relied on“Intervention+Brain-Computer”The integration of these advantages has built up a differentiated competitiveness, and with its mature commercialization capabilities, it has gained continuous recognition from the capital market.

At present, the brain-computer interface track is undergoing a reshuffle.“Pseudo-demand”“Pure Scientific Research”Companies will gradually be eliminated, while those with technical strength, clinical resources, and commercialization capabilities will become the core players in the field.

Conmind Medical with“Clinical Needs-Oriented+Technological self-reliance and controllability+Full Industry Chain Layout”The model is expected to achieve the approval and market launch of brain-computer interface products in the near future, building“Prevention-Treatment-Functional Reconstruction”The full-cycle brain medicine solution.

Notably, over the span of two years and three rounds, accumulating to more than3The financing pace of 100 million, for CONMIND MEDICAL, is not all beneficial.

The advantage lies in quickly filling the funding gap between R&D and industrialization, leveraging capital resources to accelerate technology implementation, strengthen competitiveness, and seize track opportunities; the disadvantage, however, is the need to address the pressure of capital returns and the risk of equity dilution, with the core challenge being the alignment of fund utilization efficiency and the pace of enterprise development.

Currently, the financing purpose of CONMIND MEDICAL aligns well with its development needs, and it has already commercialized some products, balancing to a certain extent the demands of capital with the original intentions of enterprise growth. However, it still needs to be vigilant against potential risks such as blind expansion and insufficient technical refinement in the future.

This recent2100 million yuanCThis round of financing is not only an important milestone for CONMIND MEDICAL, but also a microcosm of the rapid development of China's brain medicine industry. Driven by policy support, capital assistance, and clinical demand, domestic enterprises represented by CONMIND MEDICAL are gradually narrowing the gap with overseas giants, promoting China's brain medical technology from“Following”To“Running neck and neck, taking the lead”Transformation.